Skip to main content
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ADXN ISIN · CH0029850754 LEI · 89450068Y9KVP2MQGH86 SW Manufacturing
Open in API
Filings indexed 340 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country CH Switzerland
Listing SW ADXN

About Addex Therapeutics Ltd.

http://www.addextherapeutics.com/en/

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 90% confidence The document is a Form 6-K, which is a periodic report of a foreign private issuer filed with the U.S. SEC, containing risk factors and an incorporated press release. It does not present full financial statements as an annual or interim report, nor is it a management discussion, earnings release, or corporate action notice. It is a general regulatory filing, fitting the fallback category of Regulatory Filings (RNS).
2026-06-05 English
Addex Convenes Annual General Meeting 2026
Regulatory Filings Classification · 25% confidence The document is an ad hoc regulatory announcement under SIX rules announcing the date, time, location and detailed agenda of the upcoming Annual General Meeting. It does not itself provide financial statements or management commentary, nor does it present forward-looking management discussion, vote results, or formal proxy materials. It is a general regulatory notice to shareholders about the AGM, fitting the fallback category ‘Regulatory Filings (RNS).’
2026-06-05 English
FORM 20-F
Annual Report FY 2025
2026-05-15 English
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
Annual Report Classification · 95% confidence The document is an ad hoc announcement pursuant to Art. 53 LR, dated April 30, 2026, reporting full-year 2025 financial results and providing a corporate update. It includes detailed financial data for the year ended December 31, 2025, such as income, expenses, net loss, cash position, and shareholders' equity. It also references the full-year 2025 financial report available on the company's website and announces a conference call to discuss the financial results. The document contains substantive financial data and analysis for the full fiscal year 2025, indicating it is a comprehensive annual financial report rather than a brief earnings release or a report publication announcement. The presence of detailed financial statements and management commentary aligns with the characteristics of an Annual Report (10-K equivalent). Therefore, the document should be classified as an Annual Report (10-K). FY 2025
2026-04-30 English
6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Addex Therapeutics Ltd, with the SEC. It references a press release dated April 29, 2026, which is attached as Exhibit 99.1 and incorporated by reference. The text includes risk factors referencing the company's Annual Report on Form 20-F for the year ended December 31, 2024, but does not contain actual financial statements or substantive financial data itself. The document is relatively short (4614 characters) and primarily serves as a regulatory filing to report the press release and incorporate it by reference. There is no detailed financial report or earnings data presented. According to the rules, this type of document is best classified as a Regulatory Filing (RNS), as it does not constitute a full report but rather a filing that includes or references other documents.
2026-04-29 English
Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model
Regulatory Filings Classification · 82% confidence The document is an “Ad Hoc Announcement Pursuant to Art. 53 LR” disclosing preclinical data on a drug candidate’s antitussive activity. It is a press release required under listing rules, not an earnings release, report, or financial transaction. There is no detailed financial report, voting results, or call transcript present. It doesn’t fit any specialized category (10-K, ER, IR, CAP, etc.), so it falls into the fallback “Regulatory Filings” category.
2026-04-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.